Resistance to EGFR-targeted Therapy by Ets-1 Inactivation

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2015 Aug 28

PMID 26313421

Citations 3

Authors

Osamu Tetsu

David W Eisele

Frank McCormick

Affiliations

Soon will be listed here.

Citing Articles

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.

Schueler J, Tschuch C, Klingner K, Bug D, Peille A, De Koning L Cells. 2019; 8(7).

PMID: 31323891 PMC: 6678194. DOI: 10.3390/cells8070740.

ETS-targeted therapy: can it substitute for MEK inhibitors?.

Tetsu O, McCormick F Clin Transl Med. 2017; 6(1):16.

PMID: 28474232 PMC: 5418169. DOI: 10.1186/s40169-017-0147-4.

Drug Resistance to EGFR Inhibitors in Lung Cancer.

Tetsu O, Hangauer M, Phuchareon J, Eisele D, McCormick F Chemotherapy. 2016; 61(5):223-35.

PMID: 26910730 PMC: 4844777. DOI: 10.1159/000443368.

References

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Batzer A, Rotin D, Urena J, Skolnik E, Schlessinger J . Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 1994; 14(8):5192-201. PMC: 359038. DOI: 10.1128/mcb.14.8.5192-5201.1994. View

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R . Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-90. DOI: 10.1126/science.1142946. View

Phuchareon J, McCormick F, Eisele D, Tetsu O . EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 2015; 112(29):E3855-63. PMC: 4517222. DOI: 10.1073/pnas.1510733112. View

Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E . Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487(7408):505-9. PMC: 3724525. DOI: 10.1038/nature11249. View